Precision and personalized vaccines needed to face COVID-19 pandemic

Dahmani Fathallah M*

Published: 28 April, 2021 | Volume 5 - Issue 1 | Pages: 003-003

Among the abounding lessons we learned from the SARS-C0V-2 pandemic is the uttermost determinant that people are not equal before the severity of COVID-19. Indeed, the disease course differs with age, gender, ethnicity, underlying clinical conditions and virus variants. Other diseases modifying factors are associated with genetic traits such as those driving the immune response, the blood groups, the coagulation system and the ACE2 receptor variants [1-4].

Read Full Article HTML DOI: 10.29328/journal.icci.1001017 Cite this Article Read Full Article PDF


  1. Fergusson NA, Mitra AR, Griesdale DEG, Devine DV, Stukas S, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020; 4: 4981-4989. PubMed: https://pubmed.ncbi.nlm.nih.gov/33057633/
  2. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, et al. Human Leukocyte Antigen Susceptibility Map for Severe Acute B.R. Respiratory Syndrome Coronavirus 2. J Virol. 2020; 94: e00510-20. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307149/
  3. Spencer-Gold M, Sehayek D, Gabrielli S, Zhang X, McCusker C, et al. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgraduate Med. 2020; 132:8, 749-755.PubMed: https://pubmed.ncbi.nlm.nih.gov/32573311/
  4. Ashoor D, Ben Khalaf N, Marzouq M, Al Jarjanazi H, Chlif S, et al. A computational approach to evaluate the combined effect of SARS-CoV-2 RBD mutations and ACE2 receptor genetic variants on infectivity: The COVID-19 host-pathogen nexus. bioRxiv/PMC. 2021.
  5. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, et al. An Immunogenic Personal Neoantigen Vaccine for Melanoma Patients. Nature. 2017; 547: 217–221.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?